Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT07245069
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 2
- Enrolled
- 100 participants
- Registry
-
NCT07245069
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Slovenia
- Registry status
- Recruiting
Technical summary
Registry record NCT07245069. Randomized; quadruple masking; primary purpose prevention. Start 2025-02-01 (actual); primary completion 2028-11 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
- Acronym
- Alpaca
- Condition
- Heart Failure
- Condition
- Anthracycline-induced Cardiac Toxicity
- Condition
- Endothelial Function (FMD)
- Condition
- Arterial Stiffness
- Condition
- Breast Cancer
- Intervention (Drug)
- Dapagliflozin 10 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- University Medical Centre Ljubljana
Record details
- Record id
cardio:ct-nct07245069- Content hash
f5967f30cf269ce60f711c0c847aea75382e158e39ccf1fdcd9c408a084d995e